Targeted protein degradation: an interview with Ian Collins
In this interview with Ian Collins (The Institute of Cancer Research; London UK) learn more about PROTACs – Proteolysis Targeting Chimeras – a potential alternative to small molecule inhibitors. What are they? How do they work? What impact could they have on drug discovery?
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>